Abelacimab, formerly known as MAA868, represents a promising approach to treating thrombosis. This blood-thinning agent is a selective monoclonal antibody that inhibits the integrin αIIbβ3, a critical player in https://regankatj002053.blogdigy.com/abelacimab-maa868-a-deep-examination-into-the-new-blood-clot-treatment-65310968